TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Moderate, non-fistulizing Crohn's disease in the ileum and/or colon prior to randomization; and a SES-CD score of ≥7 (confirmed by centralized endoscopy reading).~* During the screening period, the participant will need to have certain average daily scores for abdominal pain and average number of liquid/very soft stools.~Major Exclusion Criteria:~* Pregnant or lactating females. Females of childbearing (reproductive) potential must have a negative serum pregnancy test at screening and agree to use a highly effective method(s) of contraception throughout their participation in the study. Diagnosis of ulcerative or indeterminate colitis.~* Diagnosis of Celiac Disease.~* Bowel surgery within 12 weeks prior to screening and/or has surgery planned or deemed likely for Crohn's disease during the study period.~* Presence of an ileostomy or colostomy.~* Known fixed symptomatic stenosis/stricture of the small or large bowel.~* Had more than one segmental colonic resection.~* Had more than 3 small bowel resections or symptoms associated with short bowel syndrome.~* Current evidence of peritonitis.~* History or evidence of colonic mucosal dysplasia.~* History or evidence of adenomatous colonic polyps that have not been removed.~* Unwilling to be tapered off corticosteroids by Week 8 or the participant is known by the Investigator to be steroid-dependent.~* Has used a biologic within 12 weeks of randomization.~* Used cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or similar drugs within 8 weeks prior to randomization.~* Had rectal administration of 5-aminosalicylic acid (5-ASA) or corticosteroid enemas/foams/ suppositories within 2 weeks prior to screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin EIR 800 mg (Type: EXPERIMENTAL): Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with recurrent malignant glioma or metastatic brain cancer requiring craniotomy for gross total resection, subtotal resection or biopsy~* Previously histopathologically proven glioma or radiographic appearance of metastatic lesion with a primary neoplasm that is known to metastasize to the brain~* Patients must have a Karnofsky performance status ≥ 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)~* Patients must have normal hematologic, renal and liver function (i.e. Hemoglobin \>10 gm/dl, Absolute neutrophil count ≥ 1500/mm3, Platelets ≥ 100,000/mm3, creatinine ≤ 1.5 mg/dl or Cr Clearance ≥ 60 mL/min, total bilirubin ≤ 1.5 mg/dl, transaminases ≤ 4 times above the upper limits of the institutional normal.~* Patients must be able to provide written informed consent~Exclusion Criteria:~* Patients with serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety~* Patients who are pregnant or breast-feeding~* Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)~* Allergy to 5HT-(3) receptor antagonist including tropisetron, ondansetron~* Patients on enzyme-inducing anticonvulsants (Dilantin, Tegretol, Phenobarbital)~* Patients with unstable angina or serious cardiovascular disease~* Known HIV positivity or AIDS-related illness~* History of allergic reaction to platinum compounds or mannitol~* Medical conditions requiring the use of oral nitrates~* Patients on alpha-1 adrenergic blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vardenafil + Carboplatin (Type: EXPERIMENTAL): Vardenafil (Levitra®) 20 mg oral administered 1 hour prior to start of craniotomy + Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
- Carboplatin Alone (Type: ACTIVE_COMPARATOR): Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Organoid Model Predictive of Response to Immunotherapies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years old at the time of informed consent~2. Ability to provide written informed consent and HIPAA authorization~3. Biopsy proven diagnosis of cancer~4. Able to obtain at least 2 16 gage cores of fresh tissue safely (3 or more cores preferred)~5. Planning to undergo standard of care Immunotherapy~6. Baseline standard of care CT within 8 weeks of starting Immunotherapy~Exclusion Criteria:~1. Inability to provide fresh biopsy sample~2. Any active infections~3. Any conditions that in the opinion of treating physician and the study team will compromise the ability of the patient to receive prescribed treatment to assess the response.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of diabetic neuropathy~* Age 18-80~* Willing to temporarily discontinue gabapentin or monoamine reuptake inhibitors upon entry into the study~Exclusion Criteria:~* Pregnancy~* Allergy to study medications~* Uncontrolled narrow-angle glaucoma~* Currently being treatment with thioridazine (Mellaril)~* Unstable medical conditions including cardiac, pulmonary, renal or hepatic diseases~* Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: ACTIVE_COMPARATOR): Donepezil 5 mg once per day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
- Duloxetine (Type: ACTIVE_COMPARATOR): Group 2: Will receive duloxetine 30 mg twice a day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
- Donepezil + Duloxetine (Type: ACTIVE_COMPARATOR): Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
- Placebo (Type: PLACEBO_COMPARATOR): Group 4:Will receive placebo pills. Gabapentin will be titrated in all groups beginning at week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Health After Birth Intervention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult aged 18 or above~* Ready and motivated to make lifestyle changes~* Have a Body Mass Index of ≥30 kg/m2 (at initial booking appointment)~Additional study specific criteria~* English speaking and ability to read English language~* Capacity to consent to participating in the study~* Are non-diabetic or those with Type 2 diabetes which is diet controlled~* Deemed medically fit by GP/medical professional to participate via email~* Have recently given birth (within 1 year)~* Are not receiving weight management support elsewhere e.g. NHS, Scottish slimmers, weight watchers~* Have access to a mobile phone and weighing scales~Exclusion Criteria:~* Have uncontrolled hypothyroidism~* Have unstable psychosis or severe and unstable personality disorder~* Are pregnant~* Have dementia~* Have moderate to severe learning disability or learning difficulty which impairs the ability to adhere to the programme (identified by medical history and confirmed with GP)~* Current alcohol or substance misuse (6 month period of abstinence)~* Active purging~* Bulimia Nervosa~* Binge Eating Disorder~Additional study specific criteria~* Known cancers~* Type 1 Diabetes or Type 2 Diabetes on any Diabetic medication (including Insulin)~* Have a pacemaker~* Renal impairment~* Taking Orlistat or any other weight loss medication or had previous bariatric surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): Adapted NHS weight management 1:1 programme. Low carbohydrate dietary focus, enhanced behaviour change via telehealth, daily step target supported by pedometers
- Active comparator NHS 1:1 weight management programme (Type: ACTIVE_COMPARATOR): 12 week NHS 1:1 weight management programme

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years~2. Willing and able to provide informed consent~3. On a stable (at least 3 months) antiretroviral therapy with DTG 50 mg QD plus one RTI~4. HIV-RNA \<50 copies/mL since at least 6 months~Exclusion Criteria:~1. Active AIDS-defining condition (except Kaposi's sarcoma non requiring systemic chemotherapy)~2. Serious illness requiring systemic treatment and/or hospitalization~3. Current use of immunomodulant or immunosuppressive drugs~4. Need (or will likely need) of treatment with antacids~5. Use of drugs contraindicated with study drugs, according to technical sheets~6. Previous suboptimal therapies with NRTIs or presence of TAMs (type 1 or 2) in previous resistance tests (patients with the 184I/V mutation alone are allowed to enter the study)~7. Resistance or previous virological failure to InSTIs~8. Detectable HCV-RNA~9. Documented allergy to COBI or EVG or FTC or tenofovir.~10. Absolute neutrophil count (ANC) \<500/µL~11. Haemoglobin \<8.0 g/dL~12. Platelet count \<50,000/µL~13. eGFR \<30 mL/min/1.73m2 by CKD-EPI equation~14. Alanine aminotransferase (ALT) more than 5 times the upper limit of normal (ULN)~15. Presence of Child Pugh Class B or C liver cirrhosis.~16. Pregnancy or breastfeeding~17. Woman of childbearing potential who does not agree to adopt highly effective contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Genvoya 150Mg-150Mg-200Mg-10Mg Table (Type: EXPERIMENTAL): switch to the treatment Genvoya 150Mg-150Mg-200Mg-10Mg Table (1 pill every 24 hour)
- Dolutegravir 50 mg plus one RTI (at label dose) (Type: ACTIVE_COMPARATOR): Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Oxygen on Lung Tissue During Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) Class I-III.~* Patient is undergoing elective surgery requiring mechanical ventilation~* Patient is an adult, 18 - 80 years old.~* Subject has voluntarily signed and dated the informed consent document approved by the Institutional Review Board (IRB).~Exclusion Criteria:~* Surgical procedures boarded for less than 2 hours~* Current Smoker~* All Cardiac, Thoracic and/or Vascular surgeries involving the chest~* Patient unable to cooperate.~* Chronic airway diseases~* Asthma~* Medical contraindication to anesthetic technique (allergy, cardiac condition, neurologic condition, localized infection, bleeding disorder).~* Subjects who are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ≥18 years old with type 1 or 2 diabetes mellitus with decreased BCVA due to center involving diabetic macular edema on spectral-domain optical coherence tomography.~2. Patients with central macular thickness CMT of ≥ 300 micrometers~Exclusion Criteria:~1. Ocular conditions that may affect macular perfusion (e.g. retinal vascular diseases, uveitis, vasculitis etc.)~2. History of vitreo-retinal surgeries.~3. Previous macular laser treatment~4. Presence of epi-retinal membrane involving the macula or vitreo-macular traction.~5. Media opacity preventing good image quality.~6. Uncontrolled glaucoma.~7. Thrombo-embolic events within 6 months~8. Previous intravitreal injections of anti-VEGF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab Group (Type: ACTIVE_COMPARATOR): Patients will receive monthly ranibizumab injections for 3 months.
- Bevacizumab Group (Type: ACTIVE_COMPARATOR): Patients will receive monthly bevacizumab injections for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diarrhea, defined as greater than 4 bowel movements per day and greater than mild; currently on no treatment or active despite treatment.~* Lymphocytic colitis confirmed histologically within one year of enrollment~Exclusion Criteria:~* Previous unsuccessful treatment with corticosteroids or immunosuppressive drugs~* History of severe corticosteroid side effects~* Corticosteroid, ticlopidine, or flutamide use within the previous 4 weeks~* Antibiotic, mesalamine or bismuth subsalicylate use within two weeks~* Current use of anticholinergics, cholestyramine, narcotics, ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, or grapefruit juice~* Known active medical conditions, including cancer, infection, uncontrolled hypertension or diabetes, osteoporosis, peptic ulcer disease, glaucoma, cataracts, liver cirrhosis or history of tuberculosis~* Other diarrheal conditions (sprue, infection, hyperthyroidism, lactose intolerance)~* Pregnant or nursing females~* Patients without a telephone or unable to communicate in English over the telephone, or unable or unwilling to give consent~* Known hypersensitivity to or intolerance of budesonide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: ACTIVE_COMPARATOR): 9 mg daily
- Placebo (Type: PLACEBO_COMPARATOR): three tablets daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preliminary Evaluation of CASTLE Barrier Prototype UK

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years of age~* has colostomy or ileostomy~* current uses two piece tape bordered barrier~* has mild to moderate peristomal skin irritation~* cares for their stoma independently in the community~* at least 3 months post-operative~* provides informed consent~Exclusion Criteria:~* has fistula on or near stoma~* has been involved in stoma care study in the last 30 days~* is pregnant or lactating (determined by interview only)~* has existing medical condition that would compromise their participation or follow-up~* currently uses convex ostomy products, paste and/or rings~* is allergic to test barrier components~* is undergoing chemo- or radiotherapy that may affect the interpretation of the results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): CASTLE Barrier

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Efficacy of SyMRI in Clinical Pediatric Populations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any stable patient undergoing clinical MRI of the brain is eligible for this study.~* Research patients undergoing research MRI of the brain for another study will be eligible.~Exclusion Criteria:~* Only those patients where an additional 10 minutes of MR imaging would not be advisable (ie. unstable, implants) or possible (due to scheduling constraints) will be excluded.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Neonates (Type: None): \<1 month of age SyMRI software used for brain imaging and radiological interpretation
- Infants (Type: None): 1mth - 2 years of age SyMRI software used for brain imaging and radiological interpretation
- Adolescents (Type: None): 2 - 12 years of age SyMRI software used for brain imaging and radiological interpretation
- Teenagers (Type: None): 13-18 years of age SyMRI software used for brain imaging and radiological interpretation
- Healthy Adults (Type: None): Preliminary Evaluation SyMRI software used for brain imaging and radiological interpretation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimisation of Hybrid Fittings for Cochlear Implant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (≥18 years of age)~2. Post-operative residual hearing in the implanted ear (defined as having an unaided threshold better than or equal to 80 dB HL at the 500 Hz frequency).~3. Implanted with the CI500 or CI24RE-series cochlear implants~4. User of the commercially available Nucleus 6 sound processor~5. User of the ACE strategy~6. Native speaker in the language used to assess speech perception performance~7. Willingness to participate in and to comply with all requirements of the protocol~Exclusion Criteria:~1. Additional handicaps that would prevent participation in evaluations~2. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and investigational device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cochlear Implant Recipients (Type: EXPERIMENTAL): Newly implanted cochlear implant recipients with post-implantation acoustic hearing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues